Michael J. Tomsicek
2016 - ABIOMED
In 2016, Michael J. Tomsicek earned a total compensation of $2.9M as Vice President, Chief Financial Officer and Treasurer at ABIOMED.
Compensation breakdown
Non-Equity Incentive Plan | $231,000 |
---|---|
Option Awards | $671,143 |
Salary | $350,000 |
Stock Awards | $1,688,750 |
Total | $2,940,893 |
Tomsicek received $1.7M in stock awards, accounting for 57% of the total pay in 2016.
Tomsicek also received $231K in non-equity incentive plan, $671.1K in option awards and $350K in salary.
Rankings
In 2016, Michael J. Tomsicek's compensation ranked 3,268th out of 14,075 executives tracked by ExecPay. In other words, Tomsicek earned more than 76.8% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 3,268 | 77th |
Manufacturing | 1,132 | 79th |
Measuring, Analyzing, And Controlling Instruments; Photographic, Medical And Optical Goods; Watches And Clocks | 143 | 83rd |
Surgical, Medical, And Dental Instruments And Supplies | 75 | 85th |
Surgical and Medical Instruments and Apparatus | 44 | 86th |
Tomsicek's colleagues
We found five more compensation records of executives who worked with Michael J. Tomsicek at ABIOMED in 2016.
2016
Michael Minogue
ABIOMED
Chief Executive Officer
2016
David Weber
ABIOMED
Chief Operating Officer
2016
Robert Bowen
ABIOMED
Chief Financial Officer
2016
Michael Howley
ABIOMED
Vice President and General Manager, Global Sales
2016
William Bolt
ABIOMED
Senior Vice President, Global Operations
News
CRISPR Therapeutics AG CEO Samarth Kulkarni's 2021 pay jumps 87% to $17M
April 25, 2022
CRISPR Therapeutics AG CEO Samarth Kulkarni's 2020 pay falls 44% to $9.1M
April 28, 2021
CRISPR Therapeutics AG CEO Samarth Kulkarni's 2019 pay jumps 67% to $16M
April 24, 2020
CRISPR Therapeutics AG CEO Samarth Kulkarni's 2018 pay jumps 40% to $9.7M
April 30, 2019
ABIOMED CEO Michael Minogue's 2018 pay slips 16% to $10M
June 22, 2018